59 institutions hold shares in Pluristem Therapeutics Inc. (PSTI), with 6.29M shares held by insiders accounting for 19.94% while institutional investors hold 14.53% of the company’s shares. The shares outstanding are 25.66M, and float is at 23.84M with Short Float at 4.14%. Institutions hold 11.64% of the Float.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The top institutional shareholder in the company is ARK Investment Management, LLC with over 3.96 million shares valued at $27.99 million. The investor’s holdings represent 12.56% of the PSTI Shares outstanding. As of Dec 30, 2020, the second largest holder is Nia Impact Advisors, LLC with 0.29 million shares valued at $2.04 million to account for 0.91% of the shares outstanding. The other top investors are Susquehanna International Group, LLP which holds 0.21 million shares representing 0.65% and valued at over $1.46 million, while Nikko Asset Management Americas, Inc. holds 0.36% of the shares totaling 0.11 million with a market value of $0.8 million.
Pluristem Therapeutics Inc. (NASDAQ: PSTI) is -8.35% lower on its value in year-to-date trading and has touched a low of $2.82 and a high of $13.29 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The PSTI stock was last observed hovering at around $6.82 in the last trading session, with the day’s loss setting it -0.34% off its average median price target of $9.00 for the next 12 months. It is also 35.2% off the consensus price target high of $10.00 offered by 5 analysts, but current levels are 7.43% higher than the price target low of $7.00 for the same period.
Currently trading at $6.48, the stock is -10.96% and -9.69% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.18 million and changing -4.99% at the moment leaves the stock -26.54% off its SMA200. PSTI registered 55.40% gain for a year compared to 6-month loss of -35.26%. The firm has a 50-day simple moving average (SMA 50) of $7.45 and a 200-day simple moving average (SMA200) of $8.92.
The stock witnessed a -14.29% gain in the last 1 month and extending the period to 3 months gives it a -29.33%, and is -17.45% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.57% over the week and 7.86% over the month.
Pluristem Therapeutics Inc. (PSTI) has around 146 employees, a market worth around $203.99M and $0.00M in sales. Distance from 52-week low is 129.79% and -51.24% from its 52-week high.
Pluristem Therapeutics Inc. (PSTI) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Pluristem Therapeutics Inc. (PSTI) is a “Buy”. 5 analysts offering their recommendations for the stock have an average rating of 2.00, where 1 rate it as a Hold and 0 think it is a “Overweight”. 4 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Pluristem Therapeutics Inc. is expected to release its quarterly report on 05/13/2021 and quarterly earnings per share for the current quarter are estimated at -$0.32.The EPS is expected to grow by 94.40% this year.
Pluristem Therapeutics Inc. (PSTI) Insider Activity
A total of 20 insider transactions have happened at Pluristem Therapeutics Inc. (PSTI) in the last six months, with sales accounting for 0 and purchases happening 20 times. The most recent transaction is an insider purchase by CLOVER WOLF CAPITAL – LIMITED , the company’s 10% Owner. SEC filings show that CLOVER WOLF CAPITAL – LIMITED bought 20,000 shares of the company’s common stock on Nov 30 at a price of $9.70 per share for a total of $0.19 million. Following the purchase, the insider now owns 4.08 million shares.
Pluristem Therapeutics Inc. disclosed in a document filed with the SEC on Oct 30 that CLOVER WOLF CAPITAL – LIMITED (10% Owner) bought a total of 50,000 shares of the company’s common stock. The trade occurred on Oct 30 and was made at $9.51 per share for $0.48 million. Following the transaction, the insider now directly holds 4.06 million shares of the PSTI stock.
Still, SEC filings show that on Oct 29, CLOVER WOLF CAPITAL – LIMITED (10% Owner) acquired 20,000 shares at an average price of $9.20 for $0.18 million. The insider now directly holds 4,007,589 shares of Pluristem Therapeutics Inc. (PSTI).